Abstract:Long-acting and implantable drug delivery systems (IDDSs) encompass a variety of therapeutic implements placed inside the body to exert a certain therapeutic action for an extended duration. They are classified under different categories from pharmaceutical science and regulatory perspectives. If the system is solely classified as a drug, a device, or a biologic, then the regulatory pathway is rather straightforward. However, if the system consists of two or more regulated components (drugs, medical devices, or biological products) combined prior to use, the systems are recognized as combination products. Regulatory approval for combination products is more complicated and less formalized than for the approval of each component independently. The rapid growth in combination products available in the global pharmaceutical and biotechnology marketplace has prompted both the United States Food and Drug Administration (US FDA) and the European Union (EU) to update their guidance on how such products are reviewed and approved for sale. The new EU draft guidance, Guideline on the Quality Requirements for Drug-Device Combinations, and US draft guidance, Principles of Premarket Pathways for Combination Products, are the latest attempts by each regulatory body to adequately regulate combination products. The progression of long-acting and IDDSs covers a variety of therapeutic devices placed inside the body to exert a certain therapeutic action for an extended duration. They are classified under different categories from pharmaceutical science and regulatory perspectives. The uniqueness and variety of IDDSs prevent the application of a standardized regulation for all of these products; therefore sponsors face regulatory challenges to register and market their products. This review investigates the requirements imposed by the US FDA and the European Medicines Agency (EMA) regarding regulatory challenges and guidance on how many IDDSs are classified, regulated, and introduced in the market. Businesses that want to register and maintain (IDDSs) products in the United States and the EU face two markets that are quite different from each other. These markets are not comparable to each other; their regulations are different from and independent of each other. Complete knowledge of the regulations in all their interpretation and nuances is necessary for businesses that want to market IDDS products into the United States or the EU. The regulatory classification of any IDDS, as a “drug,” “medical device,” or a “combination product,” is the foundation in determining the regulatory pathway, which ultimately determines the regulatory and quality standard requirements preceding the marketing approval. IDDSs are generally recognized as combination products as they consist of two or more regulated components (drugs, medical devices, or biological products) combined prior to use to function as a single entity.

A Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous Injection

Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective

An Industry Perspective on Compatibility Assessment of Closed System Drug-Transfer Devices for Biologics

A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)

Challenges Associated with Biological Safety Assessments for Drug-Device Combination Products

Development of a Robust Control Strategy for Fixed-Dose Combination Bilayer Tablets with Integrated Quality by Design, Statistical, and Process Analytical Technology Approach

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea

Challenges for clinical translation of long-acting and implantable drug delivery systems

Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023

Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge Gap

A Meta‐Analysis of the Safety and Immunogenicity of Pharmacokinetic Similarity Studies and Comparative Clinical Studies

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data

Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation

Risk-based approach of bioanalytical methods for clinical immunogenicity assessment of multidomain biotherapeutics

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs